Abstract: Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of N. meningitidis, and methods of use of such proteins, are provided.

Abstract: Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of N. meningitidis, and methods of use of such proteins, are provided.

Abstract: The present disclosure generally provides non-naturally-occurring polynucleotide sequences that facilitate high-level expression of one or more gene products (e.g., polypeptides, RNA) of interest in Neisseria meningitidis. Methods of use of such sequences, e.g., use in vaccine production, are also provided.

Abstract: The present disclosure generally provides non-naturally-occurring polynucleotide sequences that facilitate high-level expression of one or more gene products (e.g., polypeptides, RNA) of interest in Neisseria meningitidis. Methods of use of such sequences, e.g., use in vaccine production, are also provided.

Abstract: Formulation of vaccine antigens, containing as main components: a—) one or several DNA expressing one or several proteins in the immunized individuals and b—) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.

Abstract: Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of N. meningitidis, and methods of use of such proteins, are provided.

Abstract: Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of N. meningitidis, and methods of use of such proteins, are provided.

Abstract: Formulation of vaccine antigens, containing as main components: a-) one or several DNA expressing one or several proteins in the immunized individuals and b-) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.

Abstract: The present invention is related to field of medicine, particularly to the development of pharmaceutical composition containing the NMB1796 protein. The composition described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. The NMB1796 protein was identified as a Neisseria meningitidis outer membrane vesicle (OMV) component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation that the NMB1796 coding gene has shown, pharmaceutical compositions containing this protein have a high value as inducers of a cross-reactive immune response. The composition presented in this invention is applicable to the field of human medicine.

Abstract: The present invention is related to field of medicine, particularly to the development of pharmaceutical formulation containing NMB0606 protein. Formulation described in this invention is able to confer protection against different diseases caused or not by pathogenic agents. NMB0606 protein was identified as a Neisseria meningitidis outer membrane vesicle (OMV) component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation the NMB0606 coding gene has shown, pharmaceutical composition containing this protein has a high value as inducers of a cross-reactive immune response. Formulation presented in this invention is applicable to the field of human medicine.

Abstract: Use of a novel vaccine antigen applied in a preventive or therapeutic way against diseases in general, being such disease of bacterial, viral, cancer related, or other origin. The technical objective that this invention pursues is the development of formulations with the ability to increase the protective spectrum of existing vaccines and hence expanding it against different pathogens. In order to achieve this goal the NMB1125 protein was isolated and identified as a component of outer membrane preparations of Neisseria meningitidis capable of inducing bactericidal activity. Additionally, the gene codifying for NMB1125 protein was cloned and expressed, and the said polypeptide was purified and its immunogenicity evaluated in animal models. The sequence data from homologous genes showed, due to the high degree of conservation, its high value as a target antigen of a cross-reactive response when it is presented by different routes.

Abstract: The present invention is related to field of medicine, particularly to the development of pharmaceutical formulation containing NMB0938 protein. Formulation described in this invention is able to confer protection against different diseases caused or not by pathogenic agents. NMB0938 protein was identified as a Neisseria meningitidis outer membrane vesicle (OMV) component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation the NMB0938 coding gene has shown, pharmaceutical compositions containing this protein have a high value as inducers of a cross-reactive immune response. Formulation presented in this invention is applicable to the field of human medicine.

Abstract: The present invention is related to field of medicine, particularly to the development of pharmaceutical formulations containing NMA0939 protein. Formulations described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. NMA0939 protein was identified as a Neisseria meningitidis outer membrane vesicle component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation the NMA0939 coding gene has shown, pharmaceutical compositions containing this protein have a high value as inducers of a cross-reactive immune response. Formulations presented in this invention are applicable to the field of human medicine.

Abstract: Method for the insertion of protein antigens, of recombinant or synthetic origin, in outer membrane vesicles of Gram-negative bacteria without disruption of the vesicle structure, therefore maintaining the immunogenicity and immunostimulatory properties of said vesicles, and with the reported advantage that the immune response generated against the incorporated antigen is superior to the one generated when the antigen is administered alone. The resultant vaccine formulations are useful to increase protective capacity of existing vaccines and allow to extend it against different pathogens, in diseases of bacterial, viral, cancerous or other etiology. The referred formulations are applicable in the pharmaceutical industry as vaccines for therapeutic and preventive use in humans.

Abstract: The present invention describes a method of selective peptide isolation for the identification and quantitative analysis of proteins in complex mixture. The method comprises the selective isolation from every protein of those peptides that neither contain arginine nor histidine (NHNR peptides), and the determination of the relative concentrations of one or several proteins in different samples from the ratio between the areas of the estimated theoretical spectra for the NHNR peptides labeled with different isotopes in each sample. The determination of the relative concentration of proteins is valid for any type of isotopic label of the NHNR peptides. The method avoids the separation and purification of the proteins present in a complex mixture, and the analysis of all peptides generated from the enzymatic digest of the samples. The method is applicable to the identification of proteins with vacunal, therapeutic and diagnostic aims.

Abstract: Formulation of vaccine antigens, containing as main components: a-) one or several DNA expressing one or several proteins in the immunized individuals and b-) a viral antigen, in appropriate proportions. The novelty of the invention is given by the enhancing effect of at least one component on the immune response generated against the other one.